There is no evidence PET (polyethylene terephthalate) packaging poses a threat to health but use of phthalate excipients should be minimized according to an Indian Government committee.
Know-how underpinning the tech astronauts use to detect infections in space could streamline cell therapy manufacturing according to new GE Healthcare partner LeukoDx.
Plasticell has teamed up with encapsulation and screening tech firm Sphere Fluidics to develop genetic modification technology for cell therapy production.
When pharmaceutical companies miss their capacity forecast, it is both costly and time consuming, so many are choosing to outsource in order to mitigate risks.
Drug companies should share more details of their APIs and the green credentials of the companies that supply says an award winning environmental researcher.
The partnership with recombinant protein development firm GTP Technologies will create an end-to-end manufacturing service, speeding up production of monoclonal antibodies and reducing costs, says Novasep.
The global contract and manufacturing organization (CDMO) announced the construction at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site.
Drug companies were a more important source of revenue for Lonza in 2015 than in previous years with four of its five biggest spending customers coming from the pharmaceutical sector.
The changeover time between batches is significantly quicker using disposable equipment, says Avid Bioservices whose new biomanufacturing facility boasts several 1,000L single-use bioreactors.
Lonza has launched a reformulated CHO media that it says supports the growth of higher density cultures and is easier to filter than currently available products.
AAIPharma and Cambridge Major Labs (CML) under a merged entity have driven efficiencies in end-to-end drug manufacturing, the firm says, dramatically reducing material delivery time.
MaSTherCell has completed test runs of T-cell therapy Ovasave says TxCell which has reiterated its intention to restart a trial of the drug in Crohn's disease this year.
JHL has completed “mechanical construction” of an off-the-shelf mAb plant in Wuhan, China days after UK regulators gave the go ahead for a trial of its rituximab biosimilar, JHL1101.
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement in which ICIG will acquire all shares in Sandoz Industrial Products GmbH.
Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.
Sanofi is poised to terminate its Auvi-Q marketing deal says PDL Biopharma, citing manufacturing issues last year which led to a complete recall of the epinephrine injection product.
Research examining how API particle characteristics impact drug stability will help safeguard Denmark’s $12bn (DKK80bn) a year drug manufacturing industry say scientists.
Increased client demand for analytical testing has driven merged CDMO AAIPharma/Cambridge Major Laboratories to invest $11m into a new facility in Missouri.
ScinoPharm Taiwan announced its unaudited financial results for fiscal year 2015, and with it, plans to expand its contract businesses through strategic acquisitions.
There are concerns that pharma companies are not fully prepared to meet the new requirements on risk-assessment for excipients, even though the deadline is just a few weeks away.
Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.
Qualicaps has swapped a manufacturing technology customer for dominance of Brazil's fast growing pharmaceutical capsule market through a recent acquisition.
Moving its clinical manufacturing operations to its API and drug site in Queenborough has reduced the risk of problems during tech transfer and cut cycle times according to UK CMO Aesica.
The European Pharmacopoeia Commission (Ph. Eur.) has decided to recruit international experts to ensure the compendium evolves with the globalisation of the pharma industry.
The global active pharmaceuticals ingredients (APIs) market was $119.7 bn in 2014 and is predicted to reach $185.9 bn by 2020, according to a new report.
